34 Cell Line / Strain Development CDMOs

What is cell line / strain development and when do you need it?

Cell line development is how you turn a chosen biologic sequence into a stable, productive, manufacturable cell or strain. For most antibodies and recombinant proteins that means a CHO host; for some proteins and viral vectors it is HEK293; for simpler molecules, peptides, and many enzymes it is a microbial strain such as E. coli or Pichia (the yeast side of the work is usually called strain development rather than cell line development, but buyers shop for both under the same heading). The deliverable is not just a flask of cells. It is a documented, clonal, banked, and characterized production system with a known titer and a stability story you can defend to a regulator.

The work sits at a specific point in the timeline. You commission it once molecule discovery has converged on a lead and you are committing to make real material: tox supplies, then GMP drug substance for the clinic. It comes before, and feeds directly into, upstream and downstream process development. Get the cell line wrong and every downstream cost compounds, because you are optimizing a process around a clone that may underproduce or drift. That is why teams treat clone selection as a gating decision, not a formality.

A typical program runs in the range of three to six months from gene to a research cell bank, longer if you need a GMP master cell bank with full characterization and adventitious agent testing. The main levers a buyer actually decides on are the expression platform (which often comes with licensing terms attached), the host and vector, the productivity target in grams per liter, and how much clonality documentation and stability data you want before you lock the clone. Those choices shape your timeline, your royalty exposure, and how smoothly your eventual BLA reads.

What does a cell line / strain development CDMO actually do?

The provider takes your sequence (or your existing pool) and runs it through transfection or transformation, selection, and clone screening, usually narrowing thousands of candidates down to a short list using single-cell cloning and imaging to support a clonality claim. They run fed-batch or shake-flask assessments to rank clones on titer, growth, and product quality, then characterize the lead on the attributes that matter for your molecule: charge variants, glycosylation, aggregation, and sequence integrity.

From there the scope usually extends into banking and qualification. A good CDMO will generate a research cell bank, then a GMP master cell bank (MCB) and working cell bank (WCB), and run the genetic stability and adventitious agent testing that supports limit-of-in-vitro-cell-age (LIVCA) claims. Many also offer the natural next steps under one roof: upstream and downstream process development, analytical method development, and GMP drug substance manufacturing. Whether you want that continuity, or prefer to develop the line at one shop and manufacture at another, is a real decision with tech-transfer consequences, and it is worth deciding up front rather than discovering the seams later.

How to choose a cell line / strain development CDMO?

The right partner depends on your molecule, your timeline, and how far you intend to carry the program with one vendor. A microbial strain for a simple protein and a high-titer CHO line headed for commercial supply are different briefs, and the strongest provider for one is rarely the strongest for the other. Use the checklist below to compare candidates on the things that actually move risk and cost, then talk to two or three before you commit.

• Quality and GxP status: confirm GMP banking capability, a clonality strategy that will satisfy FDA and EMA, and a clean inspection history if the line is headed for the clinic.
• Capacity and lead time: ask for a realistic gene-to-RCB and gene-to-MCB timeline, current slot availability, and what a stability program adds, so the schedule fits your IND or first-in-human date.
• Modality and indication fit: match the platform to your molecule (CHO or HEK293 for mAbs and complex proteins, microbial for peptides and enzymes, specialist hosts for viral vectors), and check they have run programs like yours.
• Expression platform and IP terms: understand the licensing and royalty terms on the host or vector before signing, because some platforms carry downstream payments that follow the molecule for its commercial life.
• Region and regulatory track record: weigh location against your filing geographies and any data-residency or supply-chain preferences, and ask how many of their lines have reached IND or BLA.
• Data quality and transparency: insist on raw clone-screening data, stability results, and a clonality report you can drop into a regulatory filing, not just a summary slide.
• IP and confidentiality: review ownership of the developed line, escrow or transfer rights if you change manufacturers, and confidentiality terms covering your sequence and process.